{"ticker": {"uuid": "44578368-5def-4bb4-93a6-9e3af3864587", "symbol": "BIO", "name": "Bio-Rad Laboratories Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWXpQblZkU0FBM2Q1a2FCQjVFYWhSQTRFUzZMZHRuN3ZBSXVadWhOSEt3MTFCT2FRNTFWbzRmQjhycGhuU3lYSUgxdVpvV1lNeFltVTVsUUlUSWJzTEtEZmlvMW5NRzU0Q1JPaHNWR0Jodnk4Skd4bHc0TTdyeW05XzJ0S1E3QThFYVVkcG5XYzRIa1A0MTBPVVB1Z05wanFCeFlTMHVldE5WQ0lL?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T20:06:23+00:00", "published_display": "16 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Bio stock drops after CFO exit (HRMY:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE1yODRDcVZhN2hWcjVLbDllcjNXckFJekJvX19mT1hFUXM2REI1X1JvSWIzZlh5eUlSYWk3eHlBbG9NU1ZkM0RUc1RwNk9IRkw3UVdpOS1TX0lPd2pZd2VrdTVfSjh0R29lVVI4SFh4am1KS2NXSkdvaDZB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T14:47:16+00:00", "published_display": "16 Jul 2026 14:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate", "summary": "Bio-Rad Laboratories (BIO) has launched new QX700 System-compatible Vericheck ddPCR Kits for quality control in cell and gene therapy, potentially impacting investor assessment of the stock. While the company's shares show modest recent momentum and analyst targets are largely me", "url": "https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-launches-new-ddpcr-kits-following-a-fair-value-debate-2026-07-12", "source_name": "Sahm", "published_at": "2026-07-13T02:40:01", "published_display": "13 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories outlines its diagnostics and life science strategy for long-term growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQcU43QU5VN2paMjlKMG1MenptUVFzQ09zcG5WakRIV2VndlZ6NXNCZnAxZjJhY1FCT2ExX1ktRzRXcWVjSk50WGtReFJCMFRtN3JTdjJseXJSQWIweURHbXkzUEtNdDdOclZCbTYzOFd1WGZoZ08wdThaMks1T3MyTGJvNkdzYzB0LUJpbmF2Q1V0UHo5QlBVZlZiZ1dpUFktMzkwV09OdXhldTlIeGlsa1hDeTA3bDBOdjNySXR5Q1lpdV9OcHYtREFB?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Bio-Rad Laboratories (BIO)'s Activist Pressure and Sartorius Stake Review Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued", "summary": "Bio-Rad Laboratories (BIO) has experienced recent stock momentum, with shares up 6.5% over the past week, although it's still down 54.9% over five years. The stock currently trades slightly above its narrative fair value of $293, driven by expectations of growth from its ddPCR pl", "url": "https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-following-ddpcr-expansion-narrative-looks-fully-valued-2026-06-28", "source_name": "Sahm", "published_at": "2026-06-29T21:39:35", "published_display": "29 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449)", "summary": "This article provides an overview of Bio-Rad Laboratories, Inc. Class B (LSX:862449) financial data, analyst estimates, and frequently asked questions. It details past earnings, revenue, net income, and future earnings expectations, along with share price forecasts from analysts.", "url": "https://www.tradingview.com/symbols/LSX-862449/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T09:41:25", "published_display": "27 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW)", "summary": "This article provides financial actuals and estimates for Bio-Rad Laboratories, Inc. Class B (FWB: BUW), detailing income statement, balance sheet, cash flow, and valuation metrics. It includes analyst forecasts, historical price movements, earnings reports, dividend policy, empl", "url": "https://www.tradingview.com/symbols/FWB-BUW/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:41:56", "published_display": "25 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class A Actuals & Estimates (NYSE:BIO)", "summary": "This article provides an overview of Bio-Rad Laboratories, Inc. (NYSE: BIO) stock, including its current price, market capitalization, and historical performance. It also details actual and estimated financial data, analyst forecasts for its future price, and information regardin", "url": "https://www.tradingview.com/symbols/NYSE-BIO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:41:56", "published_display": "25 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (BIO) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It identifies a significant risk-reward short setup and outlines three distinct AI-generated trading st", "url": "https://news.stocktradersdaily.com/news_release/151/Price-Driven_Insight_from_BIO_for_Rule-Based_Strategy_062526023202_1782369122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T02:32:00", "published_display": "25 Jun 2026 02:32", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Stronger Results and Institutional Selling At Bio-Rad Laboratories (BIO) Has Changed Its Investment Story", "summary": "Bio-Rad Laboratories recently reported improved financial results with year-over-year revenue and net profit growth, yet institutional investors, notably First Eagle Investment, have significantly reduced their holdings. This divergence between strengthening financials and declin", "url": "https://www.sahmcapital.com/news/content/how-stronger-results-and-institutional-selling-at-bio-rad-laboratories-bio-has-changed-its-investment-story-2026-06-18", "source_name": "Sahm", "published_at": "2026-06-21T23:10:03", "published_display": "21 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(BIO) as a Liquidity Pulse for Institutional Tactics", "summary": "This article provides a detailed analysis of Bio-Rad Laboratories Inc. Class A (NYSE: BIO), highlighting its potential as a liquidity pulse for institutional tactics. It identifies a strong risk-reward setup targeting a 12.2% gain against 0.3% risk and outlines three distinct AI-", "url": "https://news.stocktradersdaily.com/news_release/9/BIO_as_a_Liquidity_Pulse_for_Institutional_Tactics_060226115001_1780458601.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-03T22:09:13", "published_display": "03 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] BIO-RAD LABORATORIES, INC. SEC Filing", "summary": "This SEC Filing (Form 144) for Bio-Rad Laboratories, Inc. (BIO) discloses a proposed sale of 700 shares of Class A Common stock by Alice Schwartz, acquired via donation on December 10, 2018. The aggregate market value of these shares is $219,296.44, to be sold on the NYSE on or a", "url": "https://www.stocktitan.net/sec-filings/BIO/144-bio-rad-laboratories-inc-sec-filing-778a2c64a765.html", "source_name": "Stock Titan", "published_at": "2026-05-28T18:40:24", "published_display": "28 May 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley files Rule 144 notice to sell 550 BIO shares (NYSE: BIO)", "summary": "Morgan Stanley Smith Barney LLC has filed a Rule 144 notice to sell 550 shares of Bio-Rad Laboratories (BIO). The filing indicates two restricted stock lots, dated July 25, 2025 (157 shares) and September 6, 2025 (393 shares), with the notice itself filed on May 11, 2026. This SE", "url": "https://www.stocktitan.net/sec-filings/BIO/144-bio-rad-laboratories-inc-sec-filing-053a39c0071d.html", "source_name": "Stock Titan", "published_at": "2026-05-28T08:10:04", "published_display": "28 May 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNXzBfOENBSmcwNEtPWHZoLTdDVk9NZ01vYVd1WnlnamxwOW1hV2czTE9fMDRaX0E1N205Z2h5d3pnb28zUS1Ja2pWQnFUM3pYYmpST1o1emxKMFRCNkRBdGpIRmhvLUw0eFFQbnpwR3dWYzczZnhRYnpKLVlpbmNPLXNxNHVISTRMV2RzVEZ4UXNhekZILXlob2xNd2EydW9TRDcwZlUySW1jU1hUWUZlbHU3RnUzYUxiZl85V2dRZ192OGhOYWU0?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Medical Device Terrain with a 3.22% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQd05lYTB1amt1eWRDS01CUkNBZDhwaDd4NGJidk11djZTRW8tU01KcFIxbkdWcld5TmhRWDlQVWlKN1d6anoxcXMxRjNqSi1VRklSUkFzMzlGSXc3UmJFTnBtWnBxYjRHT0s0M2Y4REN1cjNhLUl5ZUpmcXpUX1JJbWV6cFVNd2NxbG1NMFlyWEdUWWU5U1FsSFRoUlJoVEdYZFpPNVkwdTF5Y2N4NDAxM2ZZUGNoMTJOS3FJU1BpaUVJUTRfUnJ3TjRWSUsyRzdMQVE5MUFHOWRyMnB0UnBhcGFjckZDQQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Elliott\u2019s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNc3UyUG83Z2lGREpheWdpOHN6NUNlemt2WldhTzgyaVBTcDZ6ZGJ4Zi1Td3VQQnZzU3ZpR1JyYS1JaXJqRW4yV1l1VUt5MDRYNlBPeDNUSGZsVFQ5a0MzM2RsZ1NOVmRxY2hsTW54aWRrUmdlSnhLSlZfam1SSHFyZ3VWQ1BYaTd5ZUxvSVNVQklfYl9xNlh4WmRWLU9DS2FuMHJ4TUczeDM5dEZhS052Rw?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Bio-Rad Laboratories (BIO) After Its Recent 16% Weekly Surge?", "summary": "Bio-Rad Laboratories (BIO) recently experienced a 16.2% weekly surge, prompting a re-evaluation of its stock valuation. According to Simply Wall St's analysis, the company scores 2 out of 6 on its valuation framework and is considered fairly valued by a Discounted Cash Flow (DCF)", "url": "https://www.sahmcapital.com/news/content/is-it-time-to-reassess-bio-rad-laboratories-bio-after-its-recent-16-weekly-surge-2026-05-23", "source_name": "Sahm", "published_at": "2026-05-24T11:09:49", "published_display": "24 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class B Trade Ideas \u2014 BOATS:BIO.B", "summary": "This article aggregates trade ideas for Bio-Rad Laboratories, Inc. (BIO.B) from various traders on TradingView. Ideas range from long positions based on fundamental analysis and technical indicators like the 100 EMA and RSI, to short positions anticipated after a technical break.", "url": "https://www.tradingview.com/symbols/BOATS-BIO.B/ideas/page-2/", "source_name": "TradingView", "published_at": "2026-05-23T00:09:54", "published_display": "23 May 2026 00:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus", "summary": "Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, signaling potential pressure for operational, governance, or portfolio changes. This move comes as Bio-Rad faces a mixed share price record and holds a substantial stake in Sartorius. Investor", "url": "https://www.sahmcapital.com/news/content/elliott-stake-puts-bio-rad-turnaround-plans-and-sartorius-holding-in-focus-2026-05-20", "source_name": "Sahm", "published_at": "2026-05-21T05:39:43", "published_display": "21 May 2026 05:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories", "summary": "Activist investor Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, Inc. and plans to advocate for improved share performance. Bio-Rad's substantial investment in Sartorius, valued at approximately $5 billion, is a key focus for Elliott, repr", "url": "https://www.sahmcapital.com/news/content/why-elliott-sees-hidden-billions-inside-bio-rad-laboratories-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-20T03:40:15", "published_display": "20 May 2026 03:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Bio-Rad Laboratories (BIO) As RBC Sees Margin Upside Under New Leadership", "summary": "RBC Capital has restarted coverage of Bio-Rad Laboratories (BIO) with an Outperform rating, anticipating improved margins under new leadership and a sales recovery by 2027. This positive outlook is supported by recent share repurchases and strategic platform rollouts, reinforcing", "url": "https://www.sahmcapital.com/news/content/how-investors-are-reacting-to-bio-rad-laboratories-bio-as-rbc-sees-margin-upside-under-new-leadership-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-20T03:38:58", "published_display": "20 May 2026 03:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class B Trade Ideas \u2014 LS:862449", "summary": "This article compiles various trade ideas and analyses for Bio-Rad Laboratories, Inc. (LS:862449, NYSE:BIO) from different users on TradingView. It includes both long and short positions based on technical indicators like RSI, EMA, and pivot points, as well as fundamental analysi", "url": "https://www.tradingview.com/symbols/LS-862449/ideas/page-2/", "source_name": "TradingView", "published_at": "2026-05-16T16:39:44", "published_display": "16 May 2026 16:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Bio-Rad Laboratories, Inc. Class B \u2013 LS:862449", "summary": "This article provides information about the number of shareholders for Bio-Rad Laboratories, Inc. Class B (LS:862449). It appears to be a page from TradingView, presenting financial data and market information for the company. The core content seems to be a placeholder for shareh", "url": "https://www.tradingview.com/symbols/LS-862449/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-16T04:39:08", "published_display": "16 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "About Us | Oil & Gas Journal - Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) Stock Quote", "summary": "This article provides detailed stock information for Bio-Rad Laboratories, Inc. (NYSE:BIO), including its current price, trading volume, and performance metrics. It also lists recent news headlines related to the company, focusing on earnings reports, investor conferences, and ot", "url": "https://markets.financialcontent.com/pennwell.pennenergy/quote?Symbol=321%3A912793", "source_name": "FinancialContent", "published_at": "2026-05-15T14:10:21", "published_display": "15 May 2026 14:10", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (NYSE: BIO) EVP Engelhardt sells 550 A shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUl84c29qTml3ZjNYRFk1dDVEV1NNWmVfMTU3VUpMZFRVNTZzOXpoQWNTeVFJSUhidkdRQTNVeENUUHhfTFlPbXNqb1RYeVZSNGM2aDRVYlNVbjdyQlB5UkZJR0FJWjFWN1lvc2ItdkRZSjBldGk2VzdKemR1Z3hFUjFoSmpQdDg3REJLdk5nZ0xjSWJjVkxIRjM5RXBMdWwwQ2tmUERmNmI1bGZWVkRVXzFkaW01TG9U?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(BIO) Movement as an Input in Quant Signal Sets", "summary": "This article provides an analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), indicating weak near and mid-term sentiment but a positive long-term outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along w", "url": "https://news.stocktradersdaily.com/news_release/14/BIO_Movement_as_an_Input_in_Quant_Signal_Sets_051126093401_1778549641.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-11T21:34:00", "published_display": "11 May 2026 21:34", "sentiment": "negative", "sentiment_pct": 41, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Bio-Rad (BIO) Valuation After Q1 2026 Net Loss And Outlook Cut", "summary": "Bio-Rad Laboratories (BIO) experienced a Q1 2026 net loss of US$527.1 million and reduced revenue outlook, yet Simply Wall St's analysis suggests the stock is 19.9% undervalued with a fair value of $321.25. This valuation is based on expected growth in molecular diagnostics and p", "url": "https://www.sahmcapital.com/news/content/a-look-at-bio-rad-bio-valuation-after-q1-2026-net-loss-and-outlook-cut-2026-05-09", "source_name": "Sahm", "published_at": "2026-05-10T23:40:00", "published_display": "10 May 2026 23:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories Inc. Class A (BIO) Stock Price | Live Quotes & Charts | NYSE", "summary": "This page provides live quotes and charts for Bio-Rad Laboratories Inc. Class A (BIO) stock on the NYSE, showing a current price of $254.32, down $3.00 (-1.17%). It notes that there are no analyst ratings or earnings information currently available for the company. The page also ", "url": "https://stockstotrade.com/quote/BIO", "source_name": "StocksToTrade", "published_at": "2026-05-08T23:39:35", "published_display": "08 May 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO", "summary": "This article provides a list of recent news and press releases concerning Bio-Rad Laboratories, Inc. (NYSE: BIO), including financial results disclosures, management changes, and conference participation announcements. It covers events from early 2023 through mid-2024, highlighti", "url": "https://markets.financialcontent.com/stocks/quote/news?CurrentPage=1&ChannelType=PRESSRELEASES&Symbol=NY%3ABIO", "source_name": "FinancialContent", "published_at": "2026-05-06T14:39:06", "published_display": "06 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories (BIO) EPS Loss Revives Concerns Over Volatile Profit Narratives", "summary": "Bio-Rad Laboratories (BIO) reported a Q1 2026 basic EPS loss of US$19.55, despite an increase in quarterly revenue. This volatility in earnings, with net income swinging from a US$720 million gain to a US$527 million loss, raises concerns about the company's profit stability. Whi", "url": "https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-eps-loss-revives-concerns-over-volatile-profit-narratives-2026-05-02", "source_name": "Sahm", "published_at": "2026-05-03T14:39:17", "published_display": "03 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Weighs 2026 Outlook As Middle East Headwinds Meet Stilla Hopes", "summary": "Bio-Rad Laboratories (NYSE:BIO) has issued a cautious revenue outlook for 2026, citing a material impact from geopolitical disruptions in the Middle East, which led to a quarterly net loss of US$527.1 million despite sales being in line with guidance. The company plans to counter", "url": "https://www.sahmcapital.com/news/content/bio-rad-weighs-2026-outlook-as-middle-east-headwinds-meet-stilla-hopes-2026-05-01", "source_name": "Sahm", "published_at": "2026-05-01T08:39:17", "published_display": "01 May 2026 08:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss", "summary": "Bio-Rad Laboratories (BIO) reported Q1 2026 revenue of $592.1 million, a 1.1% increase year-over-year, and a strong operating profit increase. Despite improved operating performance and cash flow, the company posted a deeply negative diluted EPS of -19.55 due to a large GAAP net ", "url": "https://www.quiverquant.com/news/Bio-Rad+Laboratories+%28BIO%29+Releases+Q1+2026+Earnings%3A+Revenue+Up+Slightly%2C+EPS+Deeply+Negative+on+Large+GAAP+Loss", "source_name": "Quiver Quantitative", "published_at": "2026-04-30T21:30:00", "published_display": "30 Apr 2026 21:30", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call", "summary": "Bio-Rad Laboratories reported a 1.1% increase in net sales for Q1 2026, but a 4.2% decrease on a currency-neutral basis, primarily due to geopolitical conflicts in the Middle East and challenges in academic funding. The company adjusted its full-year 2026 guidance to between -3% ", "url": "https://www.sahmcapital.com/news/content/transcript-bio-rad-laboratories-q1-2026-earnings-conference-call-2026-05-01", "source_name": "Sahm", "published_at": "2026-04-30T20:10:23", "published_display": "30 Apr 2026 20:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (BIO) EVP Courtney Enloe gains shares via RSU vesting, withholds for taxes", "summary": "Bio-Rad Laboratories' EVP and General Counsel, Courtney C. Enloe, acquired 186 shares of Class A common stock through the vesting of restricted stock units (RSUs) on April 24, 2026. She subsequently had 77 shares withheld to cover tax obligations. After these transactions, her di", "url": "https://www.stocktitan.net/sec-filings/BIO/form-4-bio-rad-laboratories-inc-insider-trading-activity-a648695b1c5f.html", "source_name": "Stock Titan", "published_at": "2026-04-28T16:10:20", "published_display": "28 Apr 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (NYSE: BIO) CFO nets more shares after RSU vesting and tax withholding", "summary": "Bio-Rad Laboratories' EVP and CFO Roop Kalyan Lakkaraju acquired 1,078 shares of Class A common stock through RSU vesting on April 24, 2026. To cover tax obligations, 420 shares were disposed of at $287.84 per share, resulting in a net increase in direct holdings. After these tra", "url": "https://www.stocktitan.net/sec-filings/BIO/form-4-bio-rad-laboratories-inc-insider-trading-activity-2c1fe140a5cd.html", "source_name": "Stock Titan", "published_at": "2026-04-28T16:10:20", "published_display": "28 Apr 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Disappointing Results Hurt Bio-Rad Laboratories (BIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNTFZxX09fWUR1Nk91TVUtb0MxSHJCNWpsREMzQnh4SkNEZHZDcHFhZXpocWZGQlUzLU96WWdRQ0Y4a1NjUzk3ckZiV1pfTkM1X0xlSE9jaU9JUk5vUEN2aXprVjJsMHEwM29hZFJmblg5RHNRMjJfU3BSRXBXczRPZkZzNTFSUmVZd3BKbndna2JuVzVTOVF4Q2htdE13ZU1B?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPSTYxMFhyN2MtOVEyWWdSd1NjYzk5bHFxclJNVmlCLUdpektDWDE5THNmM3hXRXI3cDZ0bXhCZ3l5TnczbGNuSjhSdkx5cTV6ZE1oQlBsa01LLVJycS1feGIyUmxQRHNwV1gtLU9WMngwRjZRTURBRXE1YnJ4ZGtXZkRIZms3SXM?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories: This Undervalued Stock Offers Investors a Rare Combination", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxORVczUEktaG9PZ1dkMjMxWTk1TDZlUVFCX0dvbFZ6eEJTd2VXVmlFZWZZNXI0WUJ0UUFtMm4xanpSOTc0YS1VRHhBLUJ5dlBTRUxQMTNiTEkwQ2gwS1NnU3VwX1EyUVFEdVFTMmxBd0I0bDdkYTFLMTUxQzdxSFJOeG9VbXhMQTJqdmZrZ3dDN3ROMTJTaWc?oc=5", "source_name": "Morningstar", "published_at": "2024-11-11T08:00:00+00:00", "published_display": "11 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWXpQblZkU0FBM2Q1a2FCQjVFYWhSQTRFUzZMZHRuN3ZBSXVadWhOSEt3MTFCT2FRNTFWbzRmQjhycGhuU3lYSUgxdVpvV1lNeFltVTVsUUlUSWJzTEtEZmlvMW5NRzU0Q1JPaHNWR0Jodnk4Skd4bHc0TTdyeW05XzJ0S1E3QThFYVVkcG5XYzRIa1A0MTBPVVB1Z05wanFCeFlTMHVldE5WQ0lL?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T20:06:23+00:00", "published_display": "16 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Bio stock drops after CFO exit (HRMY:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE1yODRDcVZhN2hWcjVLbDllcjNXckFJekJvX19mT1hFUXM2REI1X1JvSWIzZlh5eUlSYWk3eHlBbG9NU1ZkM0RUc1RwNk9IRkw3UVdpOS1TX0lPd2pZd2VrdTVfSjh0R29lVVI4SFh4am1KS2NXSkdvaDZB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T14:47:16+00:00", "published_display": "16 Jul 2026 14:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate", "summary": "Bio-Rad Laboratories (BIO) has launched new QX700 System-compatible Vericheck ddPCR Kits for quality control in cell and gene therapy, potentially impacting investor assessment of the stock. While the company's shares show modest recent momentum and analyst targets are largely me", "url": "https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-launches-new-ddpcr-kits-following-a-fair-value-debate-2026-07-12", "source_name": "Sahm", "published_at": "2026-07-13T02:40:01", "published_display": "13 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories outlines its diagnostics and life science strategy for long-term growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQcU43QU5VN2paMjlKMG1MenptUVFzQ09zcG5WakRIV2VndlZ6NXNCZnAxZjJhY1FCT2ExX1ktRzRXcWVjSk50WGtReFJCMFRtN3JTdjJseXJSQWIweURHbXkzUEtNdDdOclZCbTYzOFd1WGZoZ08wdThaMks1T3MyTGJvNkdzYzB0LUJpbmF2Q1V0UHo5QlBVZlZiZ1dpUFktMzkwV09OdXhldTlIeGlsa1hDeTA3bDBOdjNySXR5Q1lpdV9OcHYtREFB?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Bio-Rad Laboratories (BIO)'s Activist Pressure and Sartorius Stake Review Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued", "summary": "Bio-Rad Laboratories (BIO) has experienced recent stock momentum, with shares up 6.5% over the past week, although it's still down 54.9% over five years. The stock currently trades slightly above its narrative fair value of $293, driven by expectations of growth from its ddPCR pl", "url": "https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-following-ddpcr-expansion-narrative-looks-fully-valued-2026-06-28", "source_name": "Sahm", "published_at": "2026-06-29T21:39:35", "published_display": "29 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449)", "summary": "This article provides an overview of Bio-Rad Laboratories, Inc. Class B (LSX:862449) financial data, analyst estimates, and frequently asked questions. It details past earnings, revenue, net income, and future earnings expectations, along with share price forecasts from analysts.", "url": "https://www.tradingview.com/symbols/LSX-862449/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T09:41:25", "published_display": "27 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW)", "summary": "This article provides financial actuals and estimates for Bio-Rad Laboratories, Inc. Class B (FWB: BUW), detailing income statement, balance sheet, cash flow, and valuation metrics. It includes analyst forecasts, historical price movements, earnings reports, dividend policy, empl", "url": "https://www.tradingview.com/symbols/FWB-BUW/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:41:56", "published_display": "25 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class A Actuals & Estimates (NYSE:BIO)", "summary": "This article provides an overview of Bio-Rad Laboratories, Inc. (NYSE: BIO) stock, including its current price, market capitalization, and historical performance. It also details actual and estimated financial data, analyst forecasts for its future price, and information regardin", "url": "https://www.tradingview.com/symbols/NYSE-BIO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:41:56", "published_display": "25 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (BIO) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It identifies a significant risk-reward short setup and outlines three distinct AI-generated trading st", "url": "https://news.stocktradersdaily.com/news_release/151/Price-Driven_Insight_from_BIO_for_Rule-Based_Strategy_062526023202_1782369122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T02:32:00", "published_display": "25 Jun 2026 02:32", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Stronger Results and Institutional Selling At Bio-Rad Laboratories (BIO) Has Changed Its Investment Story", "summary": "Bio-Rad Laboratories recently reported improved financial results with year-over-year revenue and net profit growth, yet institutional investors, notably First Eagle Investment, have significantly reduced their holdings. This divergence between strengthening financials and declin", "url": "https://www.sahmcapital.com/news/content/how-stronger-results-and-institutional-selling-at-bio-rad-laboratories-bio-has-changed-its-investment-story-2026-06-18", "source_name": "Sahm", "published_at": "2026-06-21T23:10:03", "published_display": "21 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(BIO) as a Liquidity Pulse for Institutional Tactics", "summary": "This article provides a detailed analysis of Bio-Rad Laboratories Inc. Class A (NYSE: BIO), highlighting its potential as a liquidity pulse for institutional tactics. It identifies a strong risk-reward setup targeting a 12.2% gain against 0.3% risk and outlines three distinct AI-", "url": "https://news.stocktradersdaily.com/news_release/9/BIO_as_a_Liquidity_Pulse_for_Institutional_Tactics_060226115001_1780458601.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-03T22:09:13", "published_display": "03 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] BIO-RAD LABORATORIES, INC. SEC Filing", "summary": "This SEC Filing (Form 144) for Bio-Rad Laboratories, Inc. (BIO) discloses a proposed sale of 700 shares of Class A Common stock by Alice Schwartz, acquired via donation on December 10, 2018. The aggregate market value of these shares is $219,296.44, to be sold on the NYSE on or a", "url": "https://www.stocktitan.net/sec-filings/BIO/144-bio-rad-laboratories-inc-sec-filing-778a2c64a765.html", "source_name": "Stock Titan", "published_at": "2026-05-28T18:40:24", "published_display": "28 May 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley files Rule 144 notice to sell 550 BIO shares (NYSE: BIO)", "summary": "Morgan Stanley Smith Barney LLC has filed a Rule 144 notice to sell 550 shares of Bio-Rad Laboratories (BIO). The filing indicates two restricted stock lots, dated July 25, 2025 (157 shares) and September 6, 2025 (393 shares), with the notice itself filed on May 11, 2026. This SE", "url": "https://www.stocktitan.net/sec-filings/BIO/144-bio-rad-laboratories-inc-sec-filing-053a39c0071d.html", "source_name": "Stock Titan", "published_at": "2026-05-28T08:10:04", "published_display": "28 May 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNXzBfOENBSmcwNEtPWHZoLTdDVk9NZ01vYVd1WnlnamxwOW1hV2czTE9fMDRaX0E1N205Z2h5d3pnb28zUS1Ja2pWQnFUM3pYYmpST1o1emxKMFRCNkRBdGpIRmhvLUw0eFFQbnpwR3dWYzczZnhRYnpKLVlpbmNPLXNxNHVISTRMV2RzVEZ4UXNhekZILXlob2xNd2EydW9TRDcwZlUySW1jU1hUWUZlbHU3RnUzYUxiZl85V2dRZ192OGhOYWU0?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Medical Device Terrain with a 3.22% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQd05lYTB1amt1eWRDS01CUkNBZDhwaDd4NGJidk11djZTRW8tU01KcFIxbkdWcld5TmhRWDlQVWlKN1d6anoxcXMxRjNqSi1VRklSUkFzMzlGSXc3UmJFTnBtWnBxYjRHT0s0M2Y4REN1cjNhLUl5ZUpmcXpUX1JJbWV6cFVNd2NxbG1NMFlyWEdUWWU5U1FsSFRoUlJoVEdYZFpPNVkwdTF5Y2N4NDAxM2ZZUGNoMTJOS3FJU1BpaUVJUTRfUnJ3TjRWSUsyRzdMQVE5MUFHOWRyMnB0UnBhcGFjckZDQQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Elliott\u2019s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNc3UyUG83Z2lGREpheWdpOHN6NUNlemt2WldhTzgyaVBTcDZ6ZGJ4Zi1Td3VQQnZzU3ZpR1JyYS1JaXJqRW4yV1l1VUt5MDRYNlBPeDNUSGZsVFQ5a0MzM2RsZ1NOVmRxY2hsTW54aWRrUmdlSnhLSlZfam1SSHFyZ3VWQ1BYaTd5ZUxvSVNVQklfYl9xNlh4WmRWLU9DS2FuMHJ4TUczeDM5dEZhS052Rw?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Bio-Rad Laboratories (BIO) After Its Recent 16% Weekly Surge?", "summary": "Bio-Rad Laboratories (BIO) recently experienced a 16.2% weekly surge, prompting a re-evaluation of its stock valuation. According to Simply Wall St's analysis, the company scores 2 out of 6 on its valuation framework and is considered fairly valued by a Discounted Cash Flow (DCF)", "url": "https://www.sahmcapital.com/news/content/is-it-time-to-reassess-bio-rad-laboratories-bio-after-its-recent-16-weekly-surge-2026-05-23", "source_name": "Sahm", "published_at": "2026-05-24T11:09:49", "published_display": "24 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class B Trade Ideas \u2014 BOATS:BIO.B", "summary": "This article aggregates trade ideas for Bio-Rad Laboratories, Inc. (BIO.B) from various traders on TradingView. Ideas range from long positions based on fundamental analysis and technical indicators like the 100 EMA and RSI, to short positions anticipated after a technical break.", "url": "https://www.tradingview.com/symbols/BOATS-BIO.B/ideas/page-2/", "source_name": "TradingView", "published_at": "2026-05-23T00:09:54", "published_display": "23 May 2026 00:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus", "summary": "Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, signaling potential pressure for operational, governance, or portfolio changes. This move comes as Bio-Rad faces a mixed share price record and holds a substantial stake in Sartorius. Investor", "url": "https://www.sahmcapital.com/news/content/elliott-stake-puts-bio-rad-turnaround-plans-and-sartorius-holding-in-focus-2026-05-20", "source_name": "Sahm", "published_at": "2026-05-21T05:39:43", "published_display": "21 May 2026 05:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories", "summary": "Activist investor Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, Inc. and plans to advocate for improved share performance. Bio-Rad's substantial investment in Sartorius, valued at approximately $5 billion, is a key focus for Elliott, repr", "url": "https://www.sahmcapital.com/news/content/why-elliott-sees-hidden-billions-inside-bio-rad-laboratories-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-20T03:40:15", "published_display": "20 May 2026 03:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Bio-Rad Laboratories (BIO) As RBC Sees Margin Upside Under New Leadership", "summary": "RBC Capital has restarted coverage of Bio-Rad Laboratories (BIO) with an Outperform rating, anticipating improved margins under new leadership and a sales recovery by 2027. This positive outlook is supported by recent share repurchases and strategic platform rollouts, reinforcing", "url": "https://www.sahmcapital.com/news/content/how-investors-are-reacting-to-bio-rad-laboratories-bio-as-rbc-sees-margin-upside-under-new-leadership-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-20T03:38:58", "published_display": "20 May 2026 03:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class B Trade Ideas \u2014 LS:862449", "summary": "This article compiles various trade ideas and analyses for Bio-Rad Laboratories, Inc. (LS:862449, NYSE:BIO) from different users on TradingView. It includes both long and short positions based on technical indicators like RSI, EMA, and pivot points, as well as fundamental analysi", "url": "https://www.tradingview.com/symbols/LS-862449/ideas/page-2/", "source_name": "TradingView", "published_at": "2026-05-16T16:39:44", "published_display": "16 May 2026 16:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Bio-Rad Laboratories, Inc. Class B \u2013 LS:862449", "summary": "This article provides information about the number of shareholders for Bio-Rad Laboratories, Inc. Class B (LS:862449). It appears to be a page from TradingView, presenting financial data and market information for the company. The core content seems to be a placeholder for shareh", "url": "https://www.tradingview.com/symbols/LS-862449/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-16T04:39:08", "published_display": "16 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "About Us | Oil & Gas Journal - Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) Stock Quote", "summary": "This article provides detailed stock information for Bio-Rad Laboratories, Inc. (NYSE:BIO), including its current price, trading volume, and performance metrics. It also lists recent news headlines related to the company, focusing on earnings reports, investor conferences, and ot", "url": "https://markets.financialcontent.com/pennwell.pennenergy/quote?Symbol=321%3A912793", "source_name": "FinancialContent", "published_at": "2026-05-15T14:10:21", "published_display": "15 May 2026 14:10", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (NYSE: BIO) EVP Engelhardt sells 550 A shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUl84c29qTml3ZjNYRFk1dDVEV1NNWmVfMTU3VUpMZFRVNTZzOXpoQWNTeVFJSUhidkdRQTNVeENUUHhfTFlPbXNqb1RYeVZSNGM2aDRVYlNVbjdyQlB5UkZJR0FJWjFWN1lvc2ItdkRZSjBldGk2VzdKemR1Z3hFUjFoSmpQdDg3REJLdk5nZ0xjSWJjVkxIRjM5RXBMdWwwQ2tmUERmNmI1bGZWVkRVXzFkaW01TG9U?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(BIO) Movement as an Input in Quant Signal Sets", "summary": "This article provides an analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), indicating weak near and mid-term sentiment but a positive long-term outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along w", "url": "https://news.stocktradersdaily.com/news_release/14/BIO_Movement_as_an_Input_in_Quant_Signal_Sets_051126093401_1778549641.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-11T21:34:00", "published_display": "11 May 2026 21:34", "sentiment": "negative", "sentiment_pct": 41, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Bio-Rad (BIO) Valuation After Q1 2026 Net Loss And Outlook Cut", "summary": "Bio-Rad Laboratories (BIO) experienced a Q1 2026 net loss of US$527.1 million and reduced revenue outlook, yet Simply Wall St's analysis suggests the stock is 19.9% undervalued with a fair value of $321.25. This valuation is based on expected growth in molecular diagnostics and p", "url": "https://www.sahmcapital.com/news/content/a-look-at-bio-rad-bio-valuation-after-q1-2026-net-loss-and-outlook-cut-2026-05-09", "source_name": "Sahm", "published_at": "2026-05-10T23:40:00", "published_display": "10 May 2026 23:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories Inc. Class A (BIO) Stock Price | Live Quotes & Charts | NYSE", "summary": "This page provides live quotes and charts for Bio-Rad Laboratories Inc. Class A (BIO) stock on the NYSE, showing a current price of $254.32, down $3.00 (-1.17%). It notes that there are no analyst ratings or earnings information currently available for the company. The page also ", "url": "https://stockstotrade.com/quote/BIO", "source_name": "StocksToTrade", "published_at": "2026-05-08T23:39:35", "published_display": "08 May 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO", "summary": "This article provides a list of recent news and press releases concerning Bio-Rad Laboratories, Inc. (NYSE: BIO), including financial results disclosures, management changes, and conference participation announcements. It covers events from early 2023 through mid-2024, highlighti", "url": "https://markets.financialcontent.com/stocks/quote/news?CurrentPage=1&ChannelType=PRESSRELEASES&Symbol=NY%3ABIO", "source_name": "FinancialContent", "published_at": "2026-05-06T14:39:06", "published_display": "06 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories (BIO) EPS Loss Revives Concerns Over Volatile Profit Narratives", "summary": "Bio-Rad Laboratories (BIO) reported a Q1 2026 basic EPS loss of US$19.55, despite an increase in quarterly revenue. This volatility in earnings, with net income swinging from a US$720 million gain to a US$527 million loss, raises concerns about the company's profit stability. Whi", "url": "https://www.sahmcapital.com/news/content/bio-rad-laboratories-bio-eps-loss-revives-concerns-over-volatile-profit-narratives-2026-05-02", "source_name": "Sahm", "published_at": "2026-05-03T14:39:17", "published_display": "03 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Weighs 2026 Outlook As Middle East Headwinds Meet Stilla Hopes", "summary": "Bio-Rad Laboratories (NYSE:BIO) has issued a cautious revenue outlook for 2026, citing a material impact from geopolitical disruptions in the Middle East, which led to a quarterly net loss of US$527.1 million despite sales being in line with guidance. The company plans to counter", "url": "https://www.sahmcapital.com/news/content/bio-rad-weighs-2026-outlook-as-middle-east-headwinds-meet-stilla-hopes-2026-05-01", "source_name": "Sahm", "published_at": "2026-05-01T08:39:17", "published_display": "01 May 2026 08:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss", "summary": "Bio-Rad Laboratories (BIO) reported Q1 2026 revenue of $592.1 million, a 1.1% increase year-over-year, and a strong operating profit increase. Despite improved operating performance and cash flow, the company posted a deeply negative diluted EPS of -19.55 due to a large GAAP net ", "url": "https://www.quiverquant.com/news/Bio-Rad+Laboratories+%28BIO%29+Releases+Q1+2026+Earnings%3A+Revenue+Up+Slightly%2C+EPS+Deeply+Negative+on+Large+GAAP+Loss", "source_name": "Quiver Quantitative", "published_at": "2026-04-30T21:30:00", "published_display": "30 Apr 2026 21:30", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call", "summary": "Bio-Rad Laboratories reported a 1.1% increase in net sales for Q1 2026, but a 4.2% decrease on a currency-neutral basis, primarily due to geopolitical conflicts in the Middle East and challenges in academic funding. The company adjusted its full-year 2026 guidance to between -3% ", "url": "https://www.sahmcapital.com/news/content/transcript-bio-rad-laboratories-q1-2026-earnings-conference-call-2026-05-01", "source_name": "Sahm", "published_at": "2026-04-30T20:10:23", "published_display": "30 Apr 2026 20:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (BIO) EVP Courtney Enloe gains shares via RSU vesting, withholds for taxes", "summary": "Bio-Rad Laboratories' EVP and General Counsel, Courtney C. Enloe, acquired 186 shares of Class A common stock through the vesting of restricted stock units (RSUs) on April 24, 2026. She subsequently had 77 shares withheld to cover tax obligations. After these transactions, her di", "url": "https://www.stocktitan.net/sec-filings/BIO/form-4-bio-rad-laboratories-inc-insider-trading-activity-a648695b1c5f.html", "source_name": "Stock Titan", "published_at": "2026-04-28T16:10:20", "published_display": "28 Apr 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (NYSE: BIO) CFO nets more shares after RSU vesting and tax withholding", "summary": "Bio-Rad Laboratories' EVP and CFO Roop Kalyan Lakkaraju acquired 1,078 shares of Class A common stock through RSU vesting on April 24, 2026. To cover tax obligations, 420 shares were disposed of at $287.84 per share, resulting in a net increase in direct holdings. After these tra", "url": "https://www.stocktitan.net/sec-filings/BIO/form-4-bio-rad-laboratories-inc-insider-trading-activity-2c1fe140a5cd.html", "source_name": "Stock Titan", "published_at": "2026-04-28T16:10:20", "published_display": "28 Apr 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Disappointing Results Hurt Bio-Rad Laboratories (BIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNTFZxX09fWUR1Nk91TVUtb0MxSHJCNWpsREMzQnh4SkNEZHZDcHFhZXpocWZGQlUzLU96WWdRQ0Y4a1NjUzk3ckZiV1pfTkM1X0xlSE9jaU9JUk5vUEN2aXprVjJsMHEwM29hZFJmblg5RHNRMjJfU3BSRXBXczRPZkZzNTFSUmVZd3BKbndna2JuVzVTOVF4Q2htdE13ZU1B?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPSTYxMFhyN2MtOVEyWWdSd1NjYzk5bHFxclJNVmlCLUdpektDWDE5THNmM3hXRXI3cDZ0bXhCZ3l5TnczbGNuSjhSdkx5cTV6ZE1oQlBsa01LLVJycS1feGIyUmxQRHNwV1gtLU9WMngwRjZRTURBRXE1YnJ4ZGtXZkRIZms3SXM?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories: This Undervalued Stock Offers Investors a Rare Combination", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxORVczUEktaG9PZ1dkMjMxWTk1TDZlUVFCX0dvbFZ6eEJTd2VXVmlFZWZZNXI0WUJ0UUFtMm4xanpSOTc0YS1VRHhBLUJ5dlBTRUxQMTNiTEkwQ2gwS1NnU3VwX1EyUVFEdVFTMmxBd0I0bDdkYTFLMTUxQzdxSFJOeG9VbXhMQTJqdmZrZ3dDN3ROMTJTaWc?oc=5", "source_name": "Morningstar", "published_at": "2024-11-11T08:00:00+00:00", "published_display": "11 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 110, "total_relevant": 50, "sentiment_summary": {"positive": 9, "negative": 9, "neutral": 32, "score": 51, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 74, "events": [{"event": "earnings", "label": "Earnings", "weight": 10.72, "count": 22}, {"event": "general", "label": "Market update", "weight": 8.95, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}], "positive_events": 9, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 296.11, "latest_week": "2026-07-10", "one_week_move": -0.3, "four_week_move": 3.6, "twelve_week_move": -1.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.575265, "market_dynamics_buy_signal": false, "relative_strength": -8.370588, "fair_value_gap": -2.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.129, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.3% over one week, +3.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 47, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Sahm", "count": 11}, {"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Stock Traders Daily", "count": 3}, {"label": "ad-hoc-news.de", "count": 2}, {"label": "StockStory", "count": 2}, {"label": "FinancialContent", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 10}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 22}, {"label": "Market update", "count": 15}, {"label": "Deals and strategy", "count": 4}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.3% over one week, +3.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs"}], "updated_at": "2026-07-17T10:03:21.971462+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}